# US 2026/0076948 A1 · Treatment of diabetic retinopathy using endothelin receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076948 A1
- Document ID: US20260076948A1
- Status: Published application
- Kind: A1
- Application number: 19/397,828
- Filed: 2025-11-21
- Published: 2026-03-19
- Earliest claimed: 2019-10-30
- Assignees: Perfuse Therapeutics, Inc.
- Applicants: Perfuse Therapeutics, Inc.
- Inventors: Sevgi Gurkan; David Floyd
- Web page: https://patentgrep.com/patent/US20260076948A1

## CPC

- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of treating diabetic retinopathy in a patient in need thereof, the method comprising a step of:
injecting an intravitreal implant composition to the back of the eye of the patient every 3 to 6 months, wherein the intravitreal implant composition comprises between about 100 μg and about 500 μg of Edonentan.

### Claim 26 (depends on 25)

The method of claim 25, wherein the Edonentan is in a crystalline form.

### Claim 27 (depends on 25)

The method of claim 25, wherein the patient is treated during the non-proliferative stages of diabetic retinopathy.

### Claim 28

A method of treating diabetic retinopathy in a patient in need thereof, comprising injecting a therapeutically effective amount of an ophthalmic preparation to the back of the eye of the patient every 3 to 6 months, wherein each ophthalmic preparation comprises Edonentan.

### Claim 29 (depends on 28)

The method of claim 28, wherein the Edonentan is in a crystalline form.

### Claim 30 (depends on 28)

The method of claim 28, wherein the ophthalmic preparation, upon injection, delivers between about 100 μg and about 500 μg of Edonentan to the back of the eye.

### Claim 31 (depends on 28)

The method of claim 28, wherein upon injection of the therapeutically effective amount of the ophthalmic preparation, the patient exhibits a decrease in diabetic retinopathy severity score as compared to baseline.

### Claim 32 (depends on 28)

The method of claim 28, wherein upon injection of the therapeutically effective amount of the ophthalmic preparation, the patient exhibits improvement in visual acuity or visual field.

### Claim 33 (depends on 28)

The method of claim 28, wherein upon injection of the therapeutically effective amount of the ophthalmic preparation, the patient exhibits a decrease in retinal neurodegeneration induced by diabetes.

### Claim 34 (depends on 28)

The method of claim 28, wherein upon injection, the therapeutically effective amount of the ophthalmic preparation improves retinal perfusion in the patient.

### Claim 35 (depends on 28)

The method of claim 28, wherein the therapeutically effective amount of the ophthalmic preparation slows macular edema complications in the patient.

### Claim 36

A method of treating diabetic retinopathy in a subject in need thereof, comprising:
injecting a composition comprising a therapeutically effective amount of Edonentan into an optical tissue of said subject having diabetic retinopathy.
